Valkyr: the repair pairing and the missing human evidence

A man stretching against a sunlit limestone wall on a terrace

Valkyr is a named combination of BPC-157 and TB-500, the most widely marketed repair pairing in the peptide market. Both are supported almost entirely by animal research. No adequate human trial of either component was identified, and none of the pairing.

Composition

  • bpc-157
  • tb-500

Overview

People arrive at this pairing after an injury, often when established care has been slow or disappointing. That context deserves a straight answer rather than a hopeful one. The animal literature on both components is genuinely interesting. The human literature is close to absent. Those two statements are both true and this page keeps them separate rather than letting the first imply the second.

Why these are grouped

Both are discussed in tissue repair research, one in gut and tendon models and the other in models related to cell migration and tissue remodelling. The market pairs them because they share a theme. No published work tested whether pairing them changes anything.

What each ingredient contributes

bpc-157

A synthetic peptide studied in rodent models of tendon, muscle, and gastrointestinal injury. No adequate human trial base exists.

tb-500

A synthetic fragment related to thymosin beta-4, studied in animal models of tissue repair and cell migration. Human data are lacking.

Combination evidence

  • No adequate controlled human trial of BPC-157, of TB-500, or of the pairing was identified.
  • No published human safety data describe either component at the exposures used in the market.
  • Widespread use in athletic circles is not evidence and is often accompanied by other interventions that could explain any recovery.

The evidence base for both components is preclinical. Animal healing models frequently fail to translate to humans, and the history of tissue repair research contains many compounds that looked strong in rodents and did nothing in people. That history is the reason for caution here.

Preclinical rationale

  • BPC-157 appears in rodent models of tendon, ligament, muscle, and gastrointestinal injury with reported effects on healing markers.
  • Thymosin beta-4 related fragments appear in models of cell migration and tissue remodelling.
  • Both are proposed to influence angiogenesis, which is a mechanism rather than a result.

What is not established

  • Whether either component accelerates healing in humans.
  • Whether the pairing adds anything over one component.
  • Human pharmacokinetics, which are not adequately characterised for either.
  • Long-term safety, including any relationship between growth and repair signalling and cell proliferation.

Questions to discuss with a physician

  • Is my injury diagnosed correctly, and what does the standard recovery timeline look like?
  • Is there any human evidence for this in my type of injury?
  • Could this mask pain in a way that leads me to reinjure myself?
  • What does the rehabilitation plan look like either way?
  • What are the risks given my history?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.